Home Newsfeeds Jefferies Downgrades Life Storage to Hold, Lowers Price Target to $97

Jefferies Downgrades Life Storage to Hold, Lowers Price Target to $97

Jefferies analyst Jonathan Petersen downgrades Life Storage (NYSE:LSI) from Buy to Hold and lowers the price target from $123 to $97.

byBenzinga Newsdesk

January 3, 2023

1 minute read

Jefferies analyst Jonathan Petersen downgrades Life Storage (NYSE:LSI) from Buy to Hold and lowers the price target from $123 to $97.

News
Rumors

China Said to be Working on Plans to Scrap System That Penalizes Airlines for Bringing Passengers with Covid Into the Country

By Charles Gross

November 4, 4:54 AM

-Bloomberg https://www.bloomberg.com/news/articles/2022-11-04/china-considers-ending-covid-flight-ban-system-that-hampers-travel#xj4y7vzkg?leadSource=uverify%20wall

FXI

Keybanc Maintains Overweight on Trade Desk, Raises Price Target to $70

By Benzinga Newsdesk

August 10, 4:38 AM

Keybanc analyst Justin Patterson maintains Trade Desk (NASDAQ:TTD) with a Overweight and raises the price target from $52 to $70.

TTD

Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street’s Most Accurate Analysts

By Lisa Levin

July 18, 8:39 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

GMRE

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst

By Vandana Singh

November 22, 2:12 PM

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

ARGX

Jefferies Downgrades Life Storage to Hold, Lowers Price Target to $97

Related Posts

China Said to be Working on Plans to Scrap System That Penalizes Airlines for Bringing Passengers with Covid Into the Country

Keybanc Maintains Overweight on Trade Desk, Raises Price Target to $70

Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street’s Most Accurate Analysts

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst